Edwards Lifesciences Co. (NYSE:EW) Receives $75.67 Average Target Price from Analysts

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) has received an average rating of "Hold" from the twenty-six brokerages that are presently covering the firm, MarketBeat Ratings reports. Sixteen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $75.67.

Several analysts have commented on EW shares. Stifel Nicolaus decreased their price target on shares of Edwards Lifesciences from $85.00 to $70.00 and set a "hold" rating for the company in a research report on Thursday, July 25th. Oppenheimer reissued an "outperform" rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Morgan Stanley restated an "equal weight" rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. Piper Sandler reduced their price target on Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. Finally, Wolfe Research raised Edwards Lifesciences from an "underperform" rating to a "peer perform" rating in a research report on Monday, July 29th.

Insider Activity

In related news, insider Larry L. Wood sold 25,000 shares of the business's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock valued at $2,657,000 in the last quarter. 1.27% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of large investors have recently bought and sold shares of the business. Crewe Advisors LLC acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $28,000. First Community Trust NA acquired a new position in Edwards Lifesciences during the second quarter worth $29,000. Webster Bank N. A. purchased a new position in Edwards Lifesciences during the second quarter valued at $39,000. FSA Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at about $30,000. Finally, Versant Capital Management Inc increased its stake in shares of Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company's stock worth $45,000 after purchasing an additional 326 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 0.4 %

NYSE EW opened at $70.20 on Wednesday. The company's 50-day simple moving average is $67.59 and its two-hundred day simple moving average is $75.91. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The company has a market capitalization of $41.40 billion, a price-to-earnings ratio of 10.13, a price-to-earnings-growth ratio of 3.81 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts' consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences's revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.59 earnings per share. Equities analysts forecast that Edwards Lifesciences will post 2.57 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.